ISARIC - Coronavirus Clinical Characterisation Consortium (ISARIC-4C)

ISARIC - 冠状病毒临床特征联盟 (ISARIC-4C)

• 批准号: MC_PC_19059
• 负责人: John Kenneth Baillie
• 金额: $ 625.5万
• 依托单位: University of Edinburgh
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_19059
• 关键词: ISARIC; Coronavirus; Clinical; Characterisation; Consortium

In 2019 new virus emerged(SARS-CoV-2) that causes a disease termed COVID-19. Thismay be mild but can also be severe, leading to viral pneumonia; about one in 100 infectedpeople are expected to die of it. There are many urgent questions that need answering tohelp control the outbreak and treat patients in the UK:• how long are people infectious, and what body fluids are infectious?• what puts people at higher risk of severe illness?• what is the best way to diagnose the disease?• who should we treat early with drugs, and which drugs cause harm?• does the immune system in some patients do more harm than good?• what other infections(such as pneumonia or flu) happen at the same time?The UK needs a coordinated response to answer these questions as quickly as possible.Over the last 8 years we have been preparing for such a major outbreak; our expert teamis ready to immediately deploy and has already started collecting data and samples fromUK cases.The ISARIC-4C study will provide a foundation for other studies, such as clinical trials ofnew treatments, to help better understand the best way to use interventions.We will provide real-time information about the course of COVID-19 while studying andthe underlying biology that explains illness severity with the goal of controlling spread andbetter treating those who contract it.

2019年出现了一种新的病毒（SARS-CoV-2），它导致了一种名为COVID-19的疾病。这可能是轻微的，但也可能是严重的，导致病毒性肺炎;大约每100名感染者中就有一人预计会死于这种疾病。有许多迫切的问题需要回答，以帮助控制疫情并治疗英国的患者：·人的传染性有多长时间？什么体液具有传染性？·是什么让人们患上严重疾病的风险更高？诊断这种疾病的最佳方法是什么？我们应该及早用药物治疗谁，哪些药物会造成伤害？某些患者的免疫系统是否弊大于利？·什么其他感染（如肺炎或流感）发生在同一时间？英国需要一个协调一致的反应来尽快回答这些问题。我们的专家团队已经做好了立即部署的准备，并且已经开始从英国病例中收集数据和样本。ISARIC-4C研究将为其他研究提供基础，例如新疗法的临床试验，帮助更好地了解使用干预措施的最佳方式。我们将提供有关COVID-19病程的实时信息，同时研究解释疾病严重程度的潜在生物学，以控制传播并更好地治疗感染者。

项目成果

Clinical features and management of human monkeypox: a retrospective observational study in the UK.

• DOI: 10.1016/s1473-3099(22)00228-6
• 发表时间: 2022-08
• 期刊: LANCET INFECTIOUS DISEASES
• 影响因子: 56.3
• 作者: Adler, Hugh;Gould, Susan;Hine, Paul;Snell, Luke B.;Wong, Waison;Houlihan, Catherine F.;Osborne, Jane C.;Rampling, Tommy;Beadsworth, Mike Bj;Duncan, Christopher Ja;Dunning, Jake;Fletcher, Tom E.;Hunter, Ewan R.;Jacobs, Michael;Khoo, Saye H.;Newsholme, William;Porter, David;Porter, Robert J.;Ratcliffe, Libuse;Schmid, Matthias L.;Semple, Malcolm G.;Tunbridge, Anne J.;Wingfield, Tom;Price, Nicholas M.
• 通讯作者: Price, Nicholas M.

Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients.

• DOI: 10.1111/irv.13039
• 发表时间: 2022-11
• 期刊: INFLUENZA AND OTHER RESPIRATORY VIRUSES
• 影响因子: 4.4
• 作者: Baruch, Joaquin;Rojek, Amanda;Kartsonaki, Christiana;Vijayaraghavan, Bharath K. T.;Goncalves, Bronner P.;Pritchard, Mark G.;Merson, Laura;Dunning, Jake;Hall, Matthew;Sigfrid, Louise;Citarella, Barbara W.;Murthy, Srinivas;Yeabah, Trokon O.;Olliaro, Piero
• 通讯作者: Olliaro, Piero

Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life.

• DOI: 10.1183/13993003.04015-2020
• 发表时间: 2021-09
• 期刊: The European respiratory journal
• 作者: Anastasio F;Barbuto S;Scarnecchia E;Cosma P;Fugagnoli A;Rossi G;Parravicini M;Parravicini P
• 通讯作者: Parravicini P

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus [version 2; peer review: 2 approved]

在 COVID-19 患者的血液制品中检测到的 SARS-CoV-2 RNA 与传染性病毒无关[第 2 版；

• 发表时间: 2020
• 期刊: Wellcome open research
• 作者: Andersson M

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.

• DOI: 10.12688/wellcomeopenres.16002.2
• 发表时间: 2020
• 期刊: Wellcome open research
• 作者: Andersson MI;Arancibia-Carcamo CV;Auckland K;Baillie JK;Barnes E;Beneke T;Bibi S;Brooks T;Carroll M;Crook D;Dingle K;Dold C;Downs LO;Dunn L;Eyre DW;Gilbert Jaramillo J;Harvala H;Hoosdally S;Ijaz S;James T;James W;Jeffery K;Justice A;Klenerman P;Knight JC;Knight M;Liu X;Lumley SF;Matthews PC;McNaughton AL;Mentzer AJ;Mongkolsapaya J;Oakley S;Oliveira MS;Peto T;Ploeg RJ;Ratcliff J;Robbins MJ;Roberts DJ;Rudkin J;Russell RA;Screaton G;Semple MG;Skelly D;Simmonds P;Stoesser N;Turtle L;Wareing S;Zambon M
• 通讯作者: Zambon M